Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.
| Distributed by / for | Preferred Pharmaceuticals, Inc. |
| NDC | 68788-6932-01 |
| Full product label | Metformin HCl Extended Release Tablets, USP, 500 mg, Generic for Glucophage XR, Pkg Size 100, Mfg: Time-Cap, Labs Inc., Farmingdale, NY, Preferred Pharmaceuticals, Anaheim, CA NDC: 68788-6932-01 |
| Recalling firm | Preferred Pharmaceuticals, Inc. |
| Distribution | Product was distributed to two medical clinics located in FL. |
| Quantity | 144 bottles |
| Recall initiated | 2020-06-17 |
| Report date | 2020-07-08 |
| Recall completed | 2024-03-21 |
| Recall number | D-1364-2020 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Anaheim CA United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗